Reports Q1 revenue $158.57M vs. $4.22M last year. “The first quarter was defined by strong execution as we advance zorevunersen into Phase 3 development for Dravet syndrome,” said Ian F. Smith, interim CEO and director of Stoke Therapeutics (STOK). “With regulatory alignment on a global Phase 3 study, a strategic collaboration with Biogen, and a balance sheet that takes the company to launch readiness, we are well-positioned to deliver the first disease-modifying therapy for Dravet syndrome to patients worldwide who need it while also continuing to invest in our pipeline.”
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on STOK:
- STOK Upcoming Earnings Report: What to Expect?
- Stoke Therapeutics remains significantly undervalued, says Canaccord
- Stoke Therapeutics: Buy Rating Affirmed Amid Strategic Developments and Strong Financial Position
- Stoke Therapeutics Advances with Strong Financial Position
- Optimistic Buy Rating for Stoke Therapeutics Driven by Promising Clinical Trials and Strategic Developments